Monday, August 31, 2026

Chevron Stock Bearish Momentum With A 3.18% Fall So Far On Monday

ViaNews Editorial Team

November 30, 2020

Chevron Stock Bearish Momentum With A 3.18% Fall So Far On Monday

Shares of Chevron slid 3.18% to $88.41 at 14:12 EST on Monday, after two successive sessions in a row of losses. The New York Stock Exchange is sliding 1.26% to $14,020.00, following yesterday's upward trend, on what up until now seems, an all-around rough trend trading session today.

Chevron's last close was $91.31, 38.81% below its 52-week high of $122.72.

Chevron's sales growth is a negative 22.6% for the present quarter and a decline by 1.1% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 96.6% and a negative 66.7%, respectively.

Year-on-year quarterly revenue growth declined by 31%, now sitting on 104.2B for the twelve trailing months.

Chevron's stock is valued at $88.41 at 14:12 EST, way under its 52-week high of $122.72 and way higher than its 52-week low of $51.60.

Chevron's value is way above its 50-day moving average of $77.71 and higher than its 200-day moving average of $83.98.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com